Solara Active Pharma Sciences Share Price
628.25+0.00 (-1.93%)
+14.71% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
SOLARANSE
Solara Active Pharma Sciences Share Price
628.25+0.00 (-1.93%)
+14.71% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | -3% | -2% | 7% |
| - | - | - | -1472% |
| - | -8% | 27% | 15% |
| -2% | -10% | -16% | -1% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
SOLARA
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
| 637.35 | ₹3085 Cr | 83.52 | 5.91 | 29.4 | -₹7 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹417 Cr | ₹382 Cr | ₹387 Cr | ₹349 Cr | ₹314 Cr | ₹319 Cr | ₹273 Cr | ₹300 Cr | ₹347 Cr | ₹363 Cr | ₹299 Cr | ₹212 Cr | ₹425 Cr | ₹352 Cr | ₹381 Cr | ₹395 Cr | ₹338 Cr | ₹330 Cr | ₹361 Cr | ₹100 Cr | ₹402 Cr | ₹406 Cr | ₹444 Cr | ₹427 Cr | ₹398 Cr | ₹348 Cr | ₹297 Cr | ₹344 Cr | ₹351 Cr | ₹330 Cr | ₹385 Cr | ₹356 Cr | ₹342 Cr | ₹303 Cr |
| ₹54 L | ₹3 Cr | ₹5 Cr | ₹0 | ₹49 L | ₹98 L | ₹6 Cr | ₹1 Cr | ₹32 L | ₹56 L | ₹2 Cr | ₹45 L | ₹1 Cr | ₹2 Cr | ₹5 Cr | ₹7 Cr | ₹4 Cr | ₹7 Cr | ₹6 Cr | ₹5 Cr | ₹3 Cr | ₹6 Cr | ₹10 Cr | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹12 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹7 Cr | ₹4 Cr | ₹1 Cr | ₹48 L |
| ₹418 Cr | ₹384 Cr | ₹392 Cr | ₹349 Cr | ₹314 Cr | ₹320 Cr | ₹279 Cr | ₹302 Cr | ₹347 Cr | ₹364 Cr | ₹301 Cr | ₹212 Cr | ₹426 Cr | ₹354 Cr | ₹385 Cr | ₹402 Cr | ₹342 Cr | ₹337 Cr | ₹367 Cr | ₹105 Cr | ₹405 Cr | ₹411 Cr | ₹454 Cr | ₹435 Cr | ₹404 Cr | ₹353 Cr | ₹309 Cr | ₹350 Cr | ₹356 Cr | ₹335 Cr | ₹392 Cr | ₹360 Cr | ₹344 Cr | ₹303 Cr |
| ₹367 Cr | ₹346 Cr | ₹356 Cr | ₹337 Cr | ₹303 Cr | ₹286 Cr | ₹252 Cr | ₹267 Cr | ₹311 Cr | ₹347 Cr | ₹315 Cr | ₹400 Cr | ₹414 Cr | ₹359 Cr | ₹358 Cr | ₹378 Cr | ₹339 Cr | ₹346 Cr | ₹375 Cr | ₹226 Cr | ₹358 Cr | ₹342 Cr | ₹373 Cr | ₹349 Cr | ₹328 Cr | ₹291 Cr | ₹271 Cr | ₹290 Cr | ₹307 Cr | ₹289 Cr | ₹344 Cr | ₹315 Cr | ₹314 Cr | ₹276 Cr |
| ₹77 Cr | ₹65 Cr | ₹62 Cr | ₹37 Cr | ₹35 Cr | ₹58 Cr | ₹51 Cr | ₹59 Cr | ₹62 Cr | ₹42 Cr | ₹11 Cr | -₹161 Cr | ₹39 Cr | ₹21 Cr | ₹53 Cr | ₹52 Cr | ₹31 Cr | ₹20 Cr | ₹20 Cr | -₹92 Cr | ₹75 Cr | ₹97 Cr | ₹109 Cr | ₹114 Cr | ₹104 Cr | ₹88 Cr | ₹62 Cr | ₹84 Cr | ₹73 Cr | ₹68 Cr | ₹71 Cr | ₹66 Cr | ₹49 Cr | ₹47 Cr |
| ₹18 Cr | ₹22 Cr | ₹28 Cr | ₹22 Cr | ₹21 Cr | ₹24 Cr | ₹29 Cr | ₹27 Cr | ₹28 Cr | ₹31 Cr | ₹31 Cr | ₹25 Cr | ₹24 Cr | ₹25 Cr | ₹22 Cr | ₹24 Cr | ₹22 Cr | ₹23 Cr | ₹21 Cr | ₹18 Cr | ₹17 Cr | ₹19 Cr | ₹25 Cr | ₹20 Cr | ₹19 Cr | ₹20 Cr | ₹20 Cr | ₹19 Cr | ₹20 Cr | ₹19 Cr | ₹22 Cr | ₹23 Cr | ₹20 Cr | ₹18 Cr |
| ₹28 Cr | ₹16 Cr | ₹10 Cr | -₹17 Cr | -₹10 Cr | ₹11 Cr | -₹2 Cr | ₹8 Cr | ₹8 Cr | -₹13 Cr | -₹167 Cr | -₹275 Cr | -₹17 Cr | -₹29 Cr | ₹5 Cr | ₹55 L | -₹19 Cr | -₹31 Cr | -₹31 Cr | -₹140 Cr | ₹30 Cr | ₹50 Cr | ₹57 Cr | ₹66 Cr | ₹57 Cr | ₹42 Cr | ₹18 Cr | ₹41 Cr | ₹29 Cr | ₹27 Cr | ₹26 Cr | ₹22 Cr | ₹10 Cr | ₹9 Cr |
| ₹28 Cr | ₹16 Cr | ₹10 Cr | -₹17 Cr | -₹10 Cr | ₹11 Cr | -₹2 Cr | ₹8 Cr | ₹8 Cr | -₹13 Cr | -₹255 Cr | -₹275 Cr | -₹17 Cr | -₹19 Cr | ₹4 Cr | ₹43 L | -₹10 Cr | -₹16 Cr | ₹2 Cr | -₹140 Cr | ₹30 Cr | ₹50 Cr | ₹57 Cr | ₹66 Cr | ₹57 Cr | ₹42 Cr | ₹18 Cr | ₹41 Cr | ₹29 Cr | ₹27 Cr | ₹26 Cr | ₹22 Cr | ₹9 Cr | ₹3 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — |
| ₹45 Cr | ₹40 Cr | ₹36 Cr | ₹36 Cr | ₹36 Cr | ₹36 Cr | ₹27 Cr | ₹26 Cr | ₹25 Cr |
| ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹4 Cr | ₹101 Cr | ₹106 Cr | ₹0 |
| ₹1203 Cr | ₹1051 Cr | ₹896 Cr | ₹1463 Cr | ₹1488 Cr | ₹1549 Cr | ₹958 Cr | ₹824 Cr | ₹739 Cr |
| ₹1203 Cr | ₹1051 Cr | ₹896 Cr | ₹1463 Cr | ₹1488 Cr | ₹1549 Cr | ₹958 Cr | ₹824 Cr | ₹739 Cr |
| ₹1253 Cr | ₹1094 Cr | ₹934 Cr | ₹1500 Cr | ₹1525 Cr | ₹1589 Cr | ₹1086 Cr | ₹956 Cr | ₹764 Cr |
| ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| ₹110 Cr | ₹114 Cr | ₹106 Cr | ₹235 Cr | ₹283 Cr | ₹155 Cr | ₹233 Cr | ₹225 Cr | ₹243 Cr |
| ₹0 | ₹0 | ₹0 | -₹79 Cr | -₹55 Cr | -₹26 Cr | ₹12 Cr | ₹33 Cr | ₹48 Cr |
| ₹19 Cr | ₹18 Cr | ₹12 Cr | ₹12 Cr | ₹34 Cr | ₹41 Cr | ₹56 Cr | ₹58 Cr | ₹25 L |
| ₹53 Cr | ₹59 Cr | ₹54 Cr | ₹49 Cr | ₹37 Cr | ₹37 Cr | ₹33 Cr | ₹29 Cr | ₹24 Cr |
| ₹183 Cr | ₹191 Cr | ₹172 Cr | ₹217 Cr | ₹299 Cr | ₹206 Cr | ₹333 Cr | ₹344 Cr | ₹315 Cr |
| — | — | — | — | — | — | — | — | — |
| ₹274 Cr | ₹248 Cr | ₹313 Cr | ₹306 Cr | ₹276 Cr | ₹309 Cr | ₹216 Cr | ₹244 Cr | ₹313 Cr |
| ₹105 Cr | ₹121 Cr | ₹168 Cr | ₹144 Cr | ₹174 Cr | ₹117 Cr | ₹157 Cr | ₹192 Cr | ₹90 Cr |
| ₹501 Cr | ₹573 Cr | ₹760 Cr | ₹649 Cr | ₹610 Cr | ₹361 Cr | ₹354 Cr | ₹214 Cr | ₹330 Cr |
| ₹14 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹5 Cr |
| ₹894 Cr | ₹944 Cr | ₹1243 Cr | ₹1101 Cr | ₹1063 Cr | ₹789 Cr | ₹730 Cr | ₹656 Cr | ₹738 Cr |
| ₹2333 Cr | ₹2232 Cr | ₹2351 Cr | ₹2821 Cr | ₹2890 Cr | ₹2588 Cr | ₹2153 Cr | ₹1960 Cr | ₹1821 Cr |
| ₹564 Cr | ₹60 Cr | ₹60 Cr | ₹4 Cr | ₹3 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹8 Cr |
| ₹665 Cr | ₹776 Cr | ₹999 Cr | ₹1001 Cr | ₹1025 Cr | ₹607 Cr | ₹707 Cr | ₹538 Cr | ₹633 Cr |
| — | — | — | — | — | — | — | — | — |
| ₹2038 Cr | ₹1896 Cr | ₹1876 Cr | ₹1868 Cr | ₹1760 Cr | ₹1675 Cr | ₹1581 Cr | ₹1309 Cr | ₹1100 Cr |
| ₹801 Cr | ₹705 Cr | ₹611 Cr | ₹528 Cr | ₹429 Cr | ₹318 Cr | ₹213 Cr | ₹121 Cr | ₹36 Cr |
| ₹1238 Cr | ₹1191 Cr | ₹1266 Cr | ₹1340 Cr | ₹1332 Cr | ₹1356 Cr | ₹1368 Cr | ₹1189 Cr | ₹1063 Cr |
| ₹205 Cr | ₹280 Cr | ₹256 Cr | ₹238 Cr | ₹239 Cr | ₹88 Cr | ₹40 Cr | ₹40 Cr | ₹71 Cr |
| ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹42 L | ₹42 L | ₹32 L | ₹41 L | ₹81 L |
| ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹42 L | ₹42 L | ₹32 L | ₹41 L | ₹81 L |
| ₹30 Cr | ₹28 Cr | ₹24 Cr | ₹29 Cr | ₹55 Cr | ₹59 Cr | ₹41 Cr | ₹36 Cr | ₹46 Cr |
| ₹30 L | ₹43 L | ₹48 L | ₹51 L | ₹48 L | ₹1 Cr | ₹3 Cr | ₹17 Cr | ₹9 Cr |
| ₹1474 Cr | ₹1503 Cr | ₹1550 Cr | ₹1633 Cr | ₹1651 Cr | ₹1530 Cr | ₹1481 Cr | ₹1312 Cr | ₹1214 Cr |
| — | — | — | — | — | — | — | — | — |
| ₹3 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹318 Cr | ₹318 Cr | ₹360 Cr | ₹558 Cr | ₹576 Cr | ₹295 Cr | ₹280 Cr | ₹214 Cr | ₹188 Cr |
| ₹439 Cr | ₹327 Cr | ₹349 Cr | ₹537 Cr | ₹490 Cr | ₹484 Cr | ₹227 Cr | ₹289 Cr | ₹263 Cr |
| ₹50 Cr | ₹4 Cr | ₹9 Cr | ₹9 Cr | ₹47 Cr | ₹199 Cr | ₹57 Cr | ₹76 Cr | ₹47 Cr |
| ₹20 Cr | ₹29 Cr | ₹19 Cr | ₹23 Cr | ₹18 Cr | ₹73 Cr | ₹40 Cr | ₹49 Cr | ₹75 Cr |
| ₹29 Cr | ₹52 Cr | ₹52 Cr | ₹60 Cr | ₹109 Cr | ₹7 Cr | ₹69 Cr | ₹20 Cr | ₹35 Cr |
| ₹858 Cr | ₹729 Cr | ₹788 Cr | ₹1188 Cr | ₹1239 Cr | ₹1058 Cr | ₹672 Cr | ₹648 Cr | ₹608 Cr |
| -₹36 Cr | -₹215 Cr | -₹455 Cr | ₹86 Cr | ₹176 Cr | ₹269 Cr | -₹58 Cr | -₹7 Cr | -₹130 Cr |
| ₹2333 Cr | ₹2232 Cr | ₹2351 Cr | ₹2821 Cr | ₹2890 Cr | ₹2588 Cr | ₹2153 Cr | ₹1960 Cr | ₹1821 Cr |
| ₹280 | ₹271 | ₹259 | ₹416 | ₹423 | ₹441 | ₹367 | ₹330 | ₹310 |
| ₹280 | ₹271 | ₹239 | ₹384 | ₹390 | ₹407 | ₹338 | ₹330 | ₹310 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|
| -₹7 Cr | ₹54 L | -₹488 Cr | -₹45 Cr | -₹91 Cr | ₹222 Cr | ₹115 Cr | ₹58 Cr | ₹20 L |
| ₹201 Cr | ₹210 Cr | ₹406 Cr | ₹187 Cr | ₹181 Cr | ₹173 Cr | ₹168 Cr | ₹148 Cr | ₹63 Cr |
| -₹38 Cr | ₹3 Cr | ₹191 Cr | ₹74 L | -₹314 Cr | -₹206 Cr | -₹16 Cr | -₹25 Cr | -₹11 Cr |
| ₹155 Cr | ₹214 Cr | ₹108 Cr | ₹143 Cr | -₹224 Cr | ₹189 Cr | ₹266 Cr | ₹181 Cr | ₹52 Cr |
| ₹153 Cr | ₹213 Cr | ₹109 Cr | ₹156 Cr | -₹242 Cr | ₹155 Cr | ₹242 Cr | ₹166 Cr | ₹49 Cr |
| -₹99 Cr | -₹37 Cr | -₹4 Cr | -₹81 Cr | -₹243 Cr | -₹106 Cr | -₹359 Cr | -₹116 Cr | -₹85 Cr |
| -₹54 Cr | -₹180 Cr | -₹106 Cr | -₹113 Cr | ₹334 Cr | ₹92 Cr | ₹97 Cr | -₹23 Cr | ₹68 Cr |
| ₹53 L | -₹4 Cr | -₹29 L | -₹38 Cr | -₹151 Cr | ₹142 Cr | -₹20 Cr | ₹27 Cr | ₹31 Cr |
| ₹4 Cr | ₹8 Cr | ₹9 Cr | ₹46 Cr | ₹198 Cr | ₹56 Cr | ₹76 Cr | ₹46 Cr | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹3 Cr | ₹14 Cr |
| ₹4 Cr | ₹4 Cr | ₹8 Cr | ₹9 Cr | ₹46 Cr | ₹198 Cr | ₹56 Cr | ₹76 Cr | ₹46 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Solara Active Pharma Sciences Share Price
628.25+0.00 (-1.93%)
+14.71% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 6 out of 9 oscillators
RSI
44.28Sell
STOCH %K
9.53Buy
MACD Level(12,26)
-3.40Sell
Ultimate Oscillator
39.38Sell
Aroon Oscillator
-36.00Sell
BOP
-0.25Sell
CCI
-94.55Neutral
Williams %R
-90.47Buy
Momentum
-9.90Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 7 out of 9 moving averages
EMA 9
648.42Sell
SMA 9
655.97Sell
EMA 21
651.74Sell
SMA 21
646.31Sell
EMA 50
650.27Sell
SMA 50
676.10Sell
EMA 200
598.65Buy
SMA 200
563.55Buy
WMA 20
650.46Sell
Pivot
Pivot
Classic
Resistance 5
694.67
Resistance 4
681.87
Resistance 3
669.07
Resistance 2
656.27
Resistance 1
648.43
Pivot
643.47
Support 1
635.63
Support 2
630.67
Support 3
617.87
Support 4
605.07
Support 5
592.27
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Solara Active Pharma Sciences Share Price
628.25+0.00 (-1.93%)
+14.71% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 41.93% | 41.93% | 42.00% | 42.00% | 42.01% | 42.01% |
| 10.71% | 11.52% | 11.59% | 11.98% | 13.58% | 14.25% |
| 3.02% | 2.79% | 2.57% | 2.46% | 1.51% | 1.44% |
| 0.87% | 0.95% | 1.18% | 1.18% | 1.18% | 1.18% |
| 43.47% | 42.81% | 42.66% | 42.38% | 41.72% | 41.12% |
Bulk & block deals
Name
First Sentier Investors Icvc - Si Indian Subcontinent All Cap Fund
The Scottish Oriental Smaller Companies Trust Plc
Junomoneta Finsol Private Limited
Junomoneta Finsol Private Limited
Junomoneta Finsol Private Limited
Junomoneta Finsol Private Limited
Tpg Growth Iv Sf Pte Ltd
Fssa Indian Subcontinent Fund
Spiracca Ventures Llp
Pronomz Ventures Llp
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 11 Nov 2026 | Purchase | 36.62 Cr | ₹663.84 | 5.52 L | Bulk | 1.145148 | NSE |
| 11 Nov 2026 | Sell | 36.62 Cr | ₹663.78 | 5.52 L | Bulk | 1.145148 | NSE |
| 16 Oct 2026 | Sell | 18.90 Cr | ₹724.62 | 2.61 L | Bulk | 0.542757 | NSE |
| 16 Oct 2026 | Purchase | 18.87 Cr | ₹724.53 | 2.60 L | Bulk | 0.54196 | NSE |
| 20 Aug 2026 | Sell | 17.71 Cr | ₹626.82 | 2.83 L | Bulk | 0.587887 | NSE |
| 20 Aug 2026 | Purchase | 17.75 Cr | ₹626.19 | 2.83 L | Bulk | 0.589774 | NSE |
| 10 Jul 2026 | Sell | 17.20 Cr | ₹573.20 | 3 L | Bulk | 0.624304 | NSE |
| 20 Jun 2025 | Sell | 12.09 Cr | ₹538.11 | 2.25 L | Bulk | 0.505154 | NSE |
| 16 Jun 2025 | Sell | 99 Cr | ₹495 | 20 L | Bulk | 4.495655 | NSE |
| 16 Jun 2025 | Purchase | 99 Cr | ₹495 | 20 L | Block | 4.495655 | NSE |
Insider trading & SAST
Client name
Motilal Oswal Finvest Limited
Mitsubishi Ufj Financial Group (Mufg)
Pronomz Ventures Llp
Poorvank Purohit
Poorvank Purohit
Vishal Mathur
Pronomz Ventures Llp
Sandeep Shashikantha Rao
Kausalya Santhanam
Pronomz Ventures Llp
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 Sep 2026 | Other | Acquisition | 4.16 | 6.49 | 0 | — | 20 L | 29 Sep 2026 | Acquisition of shares - Encumbrance Creation | 31,20,403 | SAST | 29(1) | Equity Shares |
| 14 Oct 2025 | Other | Disposal | 2.16 | 4.37 | 0 | — | 9.64 L | 01 Sep 2025 | Indirect Sale | 19,47,923 | SAST | 29(2) | — |
| 12 Jul 2025 | Promoter | Acquisition | 4.16 | 42.1 | 0 | — | 20 L | 16 Jun 2025 | Market | 2,02,31,281 | SAST | 29(2) | — |
| 01 Jul 2025 | Other | Disposal | 0.010902 | 0.3 | 29.55 L | ₹612.68 | 4.82 K | 25 Jun 2025 | Market Sale | 1,44,177 | Insider Trading | — | Equity Shares |
| 01 Jul 2025 | Other | Disposal | 0.022604 | 0.28 | 63.19 L | ₹631.88 | 10 K | 30 Jun 2025 | Market Sale | 1,34,177 | Insider Trading | — | Equity Shares |
| 27 Jun 2025 | Employee | Acquisition | 0.012371 | 0.04 | 29.79 L | ₹544.30 | 5.47 K | 23 Jun 2025 - 24 Jun 2025 | Market Purchase | 17,916 | Insider Trading | — | Equity Shares |
| 19 Jun 2025 | Promoter | Acquisition | 4.520775 | 9.71 | 99 Cr | ₹495 | 20 L | 16 Jun 2025 | Market Purchase | 46,74,424 | Insider Trading | — | Equity Shares |
| 09 Jun 2025 | Director | Acquisition | 0.00226 | 0 | 4.74 L | ₹473.99 | 1 K | 04 Jun 2025 | Market Purchase | 1,000 | Insider Trading | — | Equity Shares |
| 14 Mar 2025 | Director | Acquisition | 0.002484 | 0.01 | 5 L | ₹500.06 | 1 K | 11 Mar 2025 | Market Purchase | 1,876 | Insider Trading | — | Equity Shares |
| 06 Mar 2025 | Promoter | Acquisition | 0.033786 | 5.57 | 62.76 L | ₹461.50 | 13.60 K | 28 Feb 2025 | Market Purchase | 26,74,424 | Insider Trading | — | Equity Shares |
Solara Active Pharma Sciences Share Price
628.25+0.00 (-1.93%)
+14.71% past 1 Year
Solara Active Pharma Sciences is a young dynamic entrepreneurial and customer oriented API manufacturer. The company has a legacy of over three decades and traces its origins to the API
Corporate Actions
Date
Type
Details
Company details
Solara Active Pharma Sciences Share Price
628.25+0.00 (-1.93%)
+14.71% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Solara Active Pharma Sciences Share Price
628.25+0.00 (-1.93%)
+14.71% past 1 Year
News
1 of 20
ResultSOLARA16 Oct 2026
Solara Active Pharma Sciences reported second-quarter EBITDA of Rs 77.10 crores, up from Rs 34.73 crores in the corresponding quarter last year. EBITDA margin improved to 18.25% from 11.08% year on year, indicating stronger operating profitability. Revenue and profit after tax figures, along with sequential quarter comparisons, were not provided in the available update. No management guidance, analyst consensus comparison, or market reaction was specified.
Solara Reports Strong Year on Year Revenue Growth In Q2
Stock NewsSOLARA16 Oct 2026
Solara Active Pharma Sciences reported Q2 revenue of Rs 420.00 crores, compared with Rs 314.00 crores in the corresponding period a year earlier, indicating year on year growth of approximately 33.8%. The performance reflects improved operating momentum for the pharmaceutical active ingredients manufacturer.
The available update does not provide EBITDA, profit, margins, debt, capacity additions, corporate actions, or the stock price reaction. Revenue growth could support operating leverage and earnings improvement if sustained, but the broader financial impact cannot be assessed from the disclosed information alone.
The update is positive for Solara, while the market impact is expected to remain low because it represents a routine company-specific quarterly revenue announcement without sufficient profitability or guidance details.
Solara Reports Q2 Consolidated Profit After Year Ago Loss
Stock NewsSOLARA16 Oct 2026
Solara Active Pharma Sciences reported consolidated net profit of Rs 28.50 crores for the second quarter, compared with a consolidated net loss of Rs 10.10 crores in the corresponding quarter of the previous year. The result marks a year-on-year turnaround in profitability and may support earnings sentiment for the pharmaceutical company. No additional information on revenue, EBITDA, margins, dividends, capital expenditure, leverage, management changes, regulatory orders, or same-day share price movement was provided.
Solara Active Pharma tax demand of Rs 161.92 crores fully withdrawn
Stock NewsSOLARA28 Aug 2026
Solara Active Pharma Sciences Limited has received a tax rectification order that fully withdraws an earlier income tax demand of Rs 161.92 crores, bringing the outstanding demand down to zero. This rectification relates to a prior assessment where certain expenses claimed by the company had been disallowed, resulting in a substantial additional tax liability. With the latest order, that liability has now been nullified, materially improving the company’s visibility on contingent tax exposures and eliminating a significant overhang on its balance sheet.
The removal of the Rs 161.92 crores demand reduces potential outflows that could have affected Solara Active Pharma’s cash flows and leverage profile, thereby supporting financial flexibility for ongoing operations and future growth initiatives. By resolving the dispute in the company’s favour, the rectification order also lowers uncertainty around past assessments and may be viewed positively by lenders and equity investors who closely track large regulatory and tax-related contingent liabilities. While this development is primarily company-specific and not directly linked to broader sectoral or macro events, it is a meaningful corporate update for Solara Active Pharma, particularly given the quantum of the tax demand that has now been dropped to zero.
From an earnings perspective, the rectification reduces the risk of a sizeable one-off tax charge that might otherwise have weighed on net profit and return ratios in the relevant financial periods. The order does not, by itself, alter Solara Active Pharma’s underlying business operations in active pharmaceutical ingredients, but it removes a key financial uncertainty that the market had been monitoring. Any immediate share price reaction will depend on how investors had previously priced in the tax risk and on concurrent sector and market conditions on the trading day, yet the clarity provided by the rectification generally strengthens the company’s overall financial risk profile.
Solara Active Pharma plans Rs 55-60 crores capex in FY27 for expansion
Stock NewsSOLARA24 Jul 2026
Solara Active Pharma plans to spend Rs 55-60 crores in FY27, with about Rs 40 crores allocated to debottlenecking and Rs 10-15 crores set aside for maintenance. The company also expects annual expenditure of Rs 40-50 crores in FY28 and FY29.
The stated objective is to expand current operations and begin new ones over the next 12-18 months. This indicates a focused capacity expansion programme, which may support future revenue growth if execution remains on schedule and incremental assets are utilized efficiently.
No stock price reaction, regulatory filing number, or detailed funding mix was provided in the context. The impact on earnings, leverage, and operating margin will depend on project completion timelines, asset productivity, and the extent to which the new capacity improves throughput.
Solara Active Pharma Sciences Q1 EBITDA rises YoY, margin moderates slightly
ResultSOLARA23 Jul 2026
Solara Active Pharma Sciences has reported a year-on-year improvement in operating profitability for the latest reported quarter, driven by higher EBITDA in absolute terms, even as margin performance has moderated. The company posted Q1 EBITDA of Rs 61.90 crores, compared with Rs 57.00 crores in the same quarter last year, indicating a positive YoY trend in operating earnings at the absolute level. This reflects stronger operating profit generation on a comparable basis, which is relevant for assessing the underlying performance of the core business.
However, EBITDA margin for Q1 stood at 16.24 percent, down from 17.87 percent YoY. This suggests that while EBITDA has grown in rupee terms, the company has faced some compression in profitability relative to revenue, likely due to changes in cost structure, product mix, or pricing environment. The margin decline indicates that operating efficiency or cost pressures have affected the proportion of earnings retained from each rupee of revenue when compared to the previous year, even though headline EBITDA has increased.
Key headline metrics disclosed in the update focus on EBITDA and EBITDA margin, with no accompanying data provided on revenue, PAT, or QoQ comparisons. There is also no reference to street expectations, consensus estimates, or management commentary in the available context, and no information on immediate market reaction or stock price movement is included. In the absence of broader financial details and guidance, the update primarily signals a mixed operating performance profile: higher operating earnings in absolute terms alongside a moderation in margin. Market participants are likely to interpret the results in the context of the company’s recent trajectory, sector dynamics in active pharma ingredients and contract development and manufacturing, and any subsequent management communication or analyst commentary that may follow.
Solara Active Pharma Sciences reports strong Q1 revenue growth on YoY basis
ResultSOLARA23 Jul 2026
Solara Active Pharma Sciences has reported a healthy year-on-year improvement in its consolidated revenue for the latest reported quarter. The company’s Q1 revenue came in at Rs 381.00 crores, compared with Rs 320.00 crores in the corresponding quarter of the previous financial year. This translates into a robust double-digit growth in topline on a YoY basis, indicating improving demand conditions and better execution in its active pharmaceutical ingredients and related businesses. The reported numbers signal a positive trend in the company’s core operations, with revenue expansion suggesting either higher volumes, better realizations, or a combination of both across key product segments and geographies.
While detailed financial metrics such as EBITDA, profit after tax, and margin profiles are not provided in the available context, the clear revenue uplift underscores operational traction for Solara Active Pharma Sciences in Q1. The performance is relevant for investors tracking the broader Indian pharmaceuticals and chemicals space, as it highlights ongoing growth momentum in specialized API players. In the absence of specific street consensus data, margin commentary, or stock price reaction, the focus remains on the strong year-on-year revenue increase as the primary takeaway from these quarterly results. Market participants will likely watch subsequent disclosures for clarity on profitability, operating leverage, and guidance, but the current data point itself reflects a constructive development for the company’s near-term fundamental outlook.
Solara Active Pharma Sciences reports strong YoY growth in Q1 net profit
ResultSOLARA23 Jul 2026
Solara Active Pharma Sciences has reported a notable improvement in profitability for the latest quarterly period, with consolidated net profit for Q1 rising to Rs 16.30 crores from Rs 10.50 crores in the corresponding quarter last year. This represents a robust year-on-year increase in profit after tax, indicating better earnings performance compared to the previous year’s first quarter. The expansion in net profit suggests operational efficiencies, improved product mix, or better realisations in its active pharmaceutical ingredients and related businesses, even though detailed revenue, EBITDA and margin data are not provided in the available context.
While specific figures for revenue, EBITDA and operating margins are not mentioned, the sharp growth in consolidated net profit points to an overall strengthening of the company’s financial position during the quarter. In the absence of street consensus numbers or explicit guidance, the result can broadly be interpreted as positive on a year-on-year basis, especially given the scale of the profit increase in absolute terms. There is no information on quarter-on-quarter trends, commentary from the management, or the immediate stock price reaction, so market response and changes in investor perception must be inferred conservatively.
Given Solara Active Pharma Sciences’ role in the pharmaceutical and active pharmaceutical ingredients space, improved profitability in Q1 may enhance its ability to invest in capacity, research, or regulatory compliance over the medium term. However, without detailed segmental data, margin breakdowns, or forward-looking statements, the current assessment remains focused on the reported rise in consolidated net profit from Rs 10.50 crores to Rs 16.30 crores on a year-on-year basis, which is a clear positive development in the company’s earnings trajectory for this quarter.
Solara Active Pharma Sciences to host Q1 FY26 earnings conference call
Stock NewsSOLARA16 Jul 2026
Solara Active Pharma Sciences has scheduled its Q1 earnings conference call on July 23 at 4 pm. The call is expected to cover the company’s financial and operational performance for the first quarter of the current financial year, including revenue trajectory, margin profile and any key business developments across its active pharmaceutical ingredients and related businesses. Management will likely provide commentary on demand conditions in regulated and emerging markets, updates on client additions, and progress on strategic initiatives aimed at enhancing capacity utilization and improving profitability. Investors and analysts typically use such calls to assess the sustainability of recent performance trends, understand guidance for subsequent quarters, and evaluate the company’s capital allocation priorities.
The timing of the call within the results season suggests that Solara is aligning its communication with broader sector disclosures in the Indian pharmaceutical and healthcare space, which can help the market compare its metrics with peers on parameters such as growth, EBITDA margins and return ratios. The Q1 period is often important for tracking post-year-end momentum and any early signals on pricing, cost efficiencies, or regulatory developments impacting exports. While exact financial figures, margin movements and guidance for FY26 will only be known once the call and formal filings are completed, the scheduled event itself indicates continued engagement with the investor community and a structured approach to corporate disclosure. Market participants may closely watch management commentary for insights on earnings visibility, leverage trends, and potential pipeline or capacity-related initiatives that could influence medium-term growth expectations.
Solara Active Pharma Sciences posts strong Q4 FY26 growth with record margins
Stock NewsSOLARA15 May 2026
Solara Active Pharma Sciences has reported a robust performance for Q4 FY26, with the Managing Director highlighting a sequential revenue growth of 12 percent and a year-on-year growth of 40 percent. This marks a clear acceleration in the company’s topline momentum on both quarter-on-quarter and annual bases, indicating improving demand traction and better execution across its active pharmaceutical ingredients and related businesses.
Management further indicated that the company delivered its highest revenue, gross margin and EBITDA in the last eight quarters. Achieving peak levels on all three key operating parameters over a two-year period points to a combination of volume growth, an improved product mix, and operating leverage. Higher gross margin suggests better pricing power or a favorable shift in product and customer mix, while record EBITDA indicates tighter cost controls and improved operating efficiency.
The sharp year-on-year growth in Q4 FY26 also suggests a recovery from previous weaker quarters and could support improved profitability trends if sustained. For investors and analysts, the latest quarterly performance may lead to upgrades in revenue and earnings expectations if similar momentum continues into subsequent quarters. However, detailed financial disclosures, including absolute revenue, EBITDA figures, net profit, debt metrics and guidance, will be needed to fully assess the impact on Solara Active Pharma Sciences’ long-term earnings trajectory, balance sheet strength and competitive positioning within the Indian pharmaceutical and active pharmaceutical ingredients space.
Solara Active Pharma Sciences reports higher Q4 revenue on annual basis
ResultSOLARA15 May 2026
Solara Active Pharma Sciences reported Q4 revenue of Rs 387.00 crores versus Rs 270.00 crores in the same quarter last year, indicating strong year on year growth in operating topline. The provided update does not include EBITDA, PAT, margins, or quarter on quarter figures, so those metrics are not stated here.
The announcement is a routine quarterly operating update for the pharmaceuticals and active pharmaceutical ingredients business. Based on the available data, the key takeaway is the expansion in revenue, while profitability and margin performance remain unconfirmed from the supplied text.
Solara Active Pharma Sciences Q4 EBITDA rises YoY but margins contract
ResultSOLARA15 May 2026
Solara Active Pharma Sciences reported an improvement in operating profitability in its latest Q4 results, with EBITDA rising to Rs 57.60 crores from Rs 45.70 crores on a year-on-year basis. This indicates a healthy increase in absolute operating profit, suggesting better scale or cost management in core operations compared with the same quarter last year.
However, despite the rise in EBITDA, the company’s EBITDA margin declined to 14.9% in Q4 from 16.62% a year earlier. The margin compression implies that input costs, pricing, product mix, or other operating expenses expanded faster than revenue growth, limiting the translation of higher activity levels into proportional profitability. The combination of higher EBITDA but lower margin points to growth accompanied by some efficiency or cost-pressure challenges during the quarter.
The data provided does not include revenue, PAT, or quarter-on-quarter comparisons, nor does it reference any management commentary or guidance. There is also no information on how these results compared with street expectations or on the immediate stock price reaction. Within the available numbers, the key takeaway is that Solara Active Pharma Sciences has delivered stronger operating profits in absolute terms but at a thinner margin profile, which investors may interpret as a mixed operating performance for the quarter.
Solara Active Pharma Q4 swings to profit from loss on year-on-year basis
ResultSOLARA15 May 2026
Solara Active Pharma Sciences reported a turnaround in its consolidated performance for the fourth quarter, posting a net profit of Rs 9.60 crores compared with a net loss of Rs 2.00 crores in the corresponding quarter last year. The sharp improvement on a year-on-year basis indicates better profitability and operational recovery versus the prior period, when the company was in the red. While detailed revenue, EBITDA, and margin numbers are not available in the provided context, the shift from loss to profit underscores enhanced cost management, better product mix, or improved capacity utilisation within the active pharmaceutical ingredients and related businesses.
The return to profitability at the PAT level is a key positive from a credit and equity perspective, as it suggests stabilisation after a challenging phase. Investors will likely focus on the sustainability of this improved earnings trajectory in subsequent quarters, along with any commentary from management on demand trends across key geographies, regulatory compliance, and capacity expansion plans. In the absence of additional information on quarter-on-quarter comparisons, margins, or guidance, the primary takeaway remains the clear year-on-year turnaround in bottom-line performance.
No details are available in the given context on revenue growth, EBITDA trends, street expectations, or immediate stock price reaction, so any inference beyond the reported profit swing would be speculative. However, in the context of Indian mid-cap pharma, a move from loss to profit at the consolidated level generally supports a constructive stance from market participants, particularly if accompanied by improving balance sheet metrics and regulatory clarity. Overall, the reported Q4 net profit marks a meaningful positive shift in Solara Active Pharma Sciences’ financial performance compared with the same quarter last year.
Solara Active Pharma Receives US FDA EIR for Puducherry Facility, Inspection Classified as VAI.
Stock NewsSOLARA28 Apr 2026
Solara Active Pharma Sciences has received an Establishment Inspection Report (EIR) from the US FDA for its Puducherry manufacturing facility. The inspection has been concluded and classified as Voluntary Action Indicated (VAI), indicating that any observations noted are not immediately critical and can be addressed voluntarily by the company without halting operations.
This development is significant for Solara, a key player in the active pharmaceutical ingredients (API) sector, as US FDA approval and positive inspection outcomes enhance credibility for exports to the US market. The Puducherry facility's compliance strengthens the company's regulatory standing, potentially supporting future capacity utilization, new product approvals, and revenue growth from international markets. VAI status typically allows continued operations while remediation plans are implemented, minimizing disruptions to earnings or supply chains.
No specific details on inspection dates, observation counts, or immediate stock price reaction are available in the provided context. This regulatory clearance aligns with positive corporate news for pharma exporters amid ongoing US FDA scrutiny of Indian facilities.
Solara Active Pharma Sciences approves Rs 112.50 final call on partly-paid rights shares, record date April 2, 2026.
Stock NewsSOLARA24 Mar 2026
Solara Active Pharma Sciences Ltd has approved the second and final call of Rs 112.50 on its partly-paid rights shares. The record date for determining eligible shareholders is set for April 2, 2026. This follows the rights issue launched in May 2024 to raise Rs 449.95 crores at Rs 375 per share (face value Rs 10, premium Rs 365), with a 1:3 ratio.
The payment structure includes application money (35%) in June 2024, first call (35%, Rs 131.25 per share) in April 2025, and final call (30%, Rs 112.50) in April 2026. The Rights Issue Committee meeting on March 24, 2026, addressed this, with announcement made via SEBI-compliant filing on March 19, 2026, by Company Secretary Pooja Jaya Kumar. Shareholders must pay to fully convert shares, potentially impacting liquidity and equity base positively upon completion.
This corporate action completes the rights issue process, strengthening capital without dilution beyond original entitlement. No stock price impact details available in disclosures.
Solara Active Pharma Sciences Faces Rs 161.92 Cr Tax Demand for AY20 from Thane Authority
Stock NewsSOLARA18 Mar 2026
Solara Active Pharma Sciences has received a tax demand of Rs 161.92 crore from the Thane tax authority pertaining to Assessment Year 2020 (AY20). The company plans to file an appeal against the order and expects no major material impact on its financials or operations from this development.
This regulatory notice falls under corporate news for the equity segment, specifically impacting the pharma sector player listed under symbols SOLARA on NSE/BSE. The tax demand arises from proceedings by the Thane authority, a common jurisdiction for such assessments in Maharashtra. Solara's proactive appeal strategy underscores confidence in contesting the liability, potentially mitigating any cash flow pressures or provisioning needs.
Key details include the exact quantum of Rs 161.92 crore, with no immediate stock price reaction specified in the update. The company's assessment of 'no major impact' suggests limited potential effects on earnings, leverage, or ongoing business momentum in active pharmaceutical ingredients manufacturing.
Solara Active Pharma Sciences Reports Q3 Revenue Growth but Net Loss Against Prior Profit.
ResultSOLARA6 Feb 2026
Solara Active Pharma Sciences announced Q3 results with revenue at Rs 340 crores, up from Rs 300 crores YoY, reflecting 13.33% growth.
However, the company posted a consolidated net loss of Rs 174 million (Rs 17.4 crores), a sharp turnaround from Rs 80 million profit in Q3 previous year.
This decline highlights operational challenges in the pharmaceutical sector, with no specific details on EBITDA, margins, or management guidance provided in the available data.
Upcoming earnings conference call is scheduled for Feb 6, 2026, for Q3 nine-month FY26 unaudited results.
Solara Active Pharma Sciences Q3FY26 EBITDA Declines 35% YoY to Rs 37.40 Crores.
ResultSOLARA6 Feb 2026
Solara Active Pharma Sciences reported Q3FY26 EBITDA of Rs 37.40 crores, down from Rs 57.60 crores in Q3FY25, reflecting a year-over-year decline. EBITDA margin contracted to 10.73% from 19.23% YoY. No revenue, PAT, or QoQ figures were disclosed in the available data. The results align with the company's earnings announcement ahead of the Q3FY26 conference call scheduled for February 06, 2026, at 3:30 PM IST, featuring MD & CEO Sandeep Rao and CFO Sarat Kumar.
Prior Q2FY26 results showed revenue at Rs 314 crores (down 10% YoY) and EBITDA at Rs 35.20 crores (down from Rs 61.50 crores YoY), indicating ongoing pressure on profitability. Management attributed Q2 performance to operational disruptions from facility upgrades at Mangalore.
Solara Active Pharma Sciences Reports Q3 FY26 Consolidated Net Loss of Rs 17.40 Crores Vs YoY Profit.
ResultSOLARA6 Feb 2026
Solara Active Pharma Sciences reported Q3 FY26 consolidated net loss of Rs 17.40 crores, compared to profit of Rs 8.00 crores YoY. Revenue stood at Rs 319.15 crores, up 16.90% QoQ from Rs 273.01 crores but down 12.20% YoY. Operating profit was Rs 24.88 crores, down 29.06% QoQ and 20.84% YoY. PBDT at Rs 23.58 crores declined 2.96% QoQ and 5.94% YoY. Profit before tax at Rs 10.52 crores showed YoY decline of 178.16%. Expenses were Rs 278.81 crores, other income Rs 0.49 crores, depreciation Rs 24.49 crores.
Context from prior quarters indicates revenue challenges, with Q2 FY26 revenue at Rs 314 crores down 10% YoY and EBITDA at Rs 35.2 crores (11.3%) vs Rs 61.5 crores (17.7%) YoY. Management noted transitory disruptions from facility upgrades impacting sales. No specific street expectations or market reaction detailed in available data.
Solara Active Pharma Sciences appoints Mohanraj S as executive director
Stock NewsSOLARA17 Dec 2025
Solara Active Pharma Sciences has approved the appointment of Mr. Mohanraj S as an Additional Executive Director and Whole-Time Director of the company for a term of three years, effective from January 1, 2026, subject to shareholder approval. The decision was taken by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee, and has been disclosed to both BSE and NSE under SEBI (LODR) regulations as a material event.
Mr. Mohanraj S, who holds DIN 08420411, brings over three decades of experience across pharmaceuticals, biotech, defence aerospace, engineering, apparel and media industries, with deep expertise in industrial relations, workforce governance and statutory and regulatory compliance. The company has clarified that he is not debarred from accessing capital markets and is not restrained from holding the office of director by SEBI or any other authority, and that he is not related to existing directors or key managerial personnel. His background includes leading long-term union settlements and managing complex, unionized environments, which may support operational stability at Solara Active Pharma Sciences.
This appointment represents a management strengthening move rather than a balance sheet or capital structure event. While no immediate financial impact or guidance change has been indicated, the addition of an experienced executive director is generally viewed as supportive for governance, compliance and medium-term execution. The market impact is likely to be stock-specific and limited to sentiment around leadership and governance rather than broader sector or index implications.

